PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Angel Guerrero-Zotano; Ingrid A. Mayer; Carlos L. Arteaga

doi:10.1007/s10555-016-9637-x

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Angel Guerrero-Zotano, Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journal › Article › peer-review

305 Scopus citations

Abstract

Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

Original language	English (US)
Pages (from-to)	515-524
Number of pages	10
Journal	Cancer and Metastasis Reviews
Volume	35
Issue number	4
DOIs	https://doi.org/10.1007/s10555-016-9637-x
State	Published - Dec 1 2016

Keywords

AKT
Breast cancer
mTOR
PI3K

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s10555-016-9637-x

Cite this

@article{6f8a6773c6544008bbd8246aeba4fbb3,

title = "PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment",

abstract = "Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.",

keywords = "AKT, Breast cancer, mTOR, PI3K",

author = "Angel Guerrero-Zotano and Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",

year = "2016",

month = dec,

day = "1",

doi = "10.1007/s10555-016-9637-x",

language = "English (US)",

volume = "35",

pages = "515--524",

journal = "Cancer and Metastasis Reviews",

issn = "0167-7659",

publisher = "Springer Netherlands",

number = "4",

}

TY - JOUR

T1 - PI3K/AKT/mTOR

T2 - role in breast cancer progression, drug resistance, and treatment

AU - Guerrero-Zotano, Angel

AU - Mayer, Ingrid A.

AU - Arteaga, Carlos L.

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

AB - Anti-cancer cancer-targeted therapies are designed to exploit a particular vulnerability in the tumor, which in most cases results from its dependence on an oncogene and/or loss of a tumor suppressor. Mutations in the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway are freqcuently found in breast cancers and associated with cellular transformation, tumorigenesis, cancer progression, and drug resistance. Several drugs targeting PI3K/ATK/mTOR are currently in clinical trials, mainly in combination with endocrine therapy and anti-HER2 therapy. These drugs are the focus of this review.

KW - AKT

KW - Breast cancer

KW - mTOR

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=84997831559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997831559&partnerID=8YFLogxK

U2 - 10.1007/s10555-016-9637-x

DO - 10.1007/s10555-016-9637-x

M3 - Article

C2 - 27896521

AN - SCOPUS:84997831559

SN - 0167-7659

VL - 35

SP - 515

EP - 524

JO - Cancer and Metastasis Reviews

JF - Cancer and Metastasis Reviews

IS - 4

ER -

PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this